Indomethacin acts as an antitumor and anticachexic agent in colon 26-bearing CDF1 mice
This study uses Colon 26-bearing CDF1 mice to assess the pharmacologic actions of indomethacin on tumor growth and cancer cachexia. The effect on tumor growth was evaluated by tumor weight, and the effect on cachexia was screened by changes in body weight and food intake. Additional indices measured included serum levels of immunosuppressive acidic protein and interleukin-6, and prostaglandin E2 content in the tumor tissues.
Indomethacin (1.0 mg/kg body weight, by oral gavage twice per day) was given to 2 groups of mice, group B (long-term therapy) for 21 days, and group C (short-term therapy) for 7 days. A control group (A) received twice-daily oral gavage of the vehicle alone.
Mean tumor weight was significantly reduced in groups B and C, compared to the control group. Group B had significantly less body weight loss, and true body weight increased significantly in group C mice from day 17, as compared with the control mice. Serum levels of immunosuppressive acidic protein were significantly reduced in both groups B and C, when compared to the nontreated controls. Serum levels of interleukin-6 were also significantly reduced in both groups B and C, compared to the controls. Prostaglandin E2 content in the tumor tissues was significantly lower in both groups B and C than it was in the controls.
Indomethacin was shown to act as an antitumor and anticachexic agent. These findings suggest a potential role for indomethacin as a therapeutic agent for cancer.
Key wordsindomethacin prostaglandin E2 interleukin-6 immunosuppressive acidic protein
- 5.Foldgren P, Sjøgren HO. Influence in vitro on NK and K cell activities by cimetidine and indomethacin with an without simultaneous exposure to interferone. Cancer Immunol Immunother 1985;19:28–34.Google Scholar
- 8.Baxevanis CN, Recols GJ, Gritzapis AD, Zedousis GVZ, Missitzis I, Papamichail M. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 1993;72:491–501.PubMedCrossRefGoogle Scholar
- 11.Bennet A, Carrol MA, Melhish PB, Stamford IF. Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin. Br J Cancer 1985;52:245–249.Google Scholar
- 12.Heneghan JB. Inhibition of human colon tumor growth in nude mice by indomethacin. In: Germfree research: microflora control and its application to biomedical science. New York: Alan R. Liss; 1985:315–318.Google Scholar
- 29.Feldmann JM, Hilf R. Failure of indomethacin to inhibit growth of the R3230 AC mammary tumor in rats. J Natl Cancer Inst 1985;75:751–756.Google Scholar
- 35.McCarthy DO, Kluger M, Vander A. Suppression of food intake during infection: is interleukin-1 involved. Am J Nutr 1985;42:1179–1182.Google Scholar
- 38.Ouchi KF, Tamura S, Mori K, Tanaka Y, Ishitsuka H. Establishment and characterization of cachexia-inducing and non-inducing clones of murine Colon 26 carcinoma. Int J Cancer 1995;61:522–528.Google Scholar